Credit Suisse analyst Judah Frommer reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $4 price target.
Credit Suisse Reiterates Outperform on Jasper Therapeutics, Maintains $4 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.